Raritan, NJ, United States of America

Thomas Courtney Gardinier, Ii

USPTO Granted Patents = 2 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Thomas Courtney Gardinier, II: Innovator in Nanoparticle Drug Conjugates

Introduction

Thomas Courtney Gardinier, II is a notable inventor based in Raritan, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative work in nanoparticle drug conjugates. With a total of 2 patents, Gardinier is recognized for his advancements in targeted drug delivery systems.

Latest Patents

Gardinier's latest patents include "Folate receptor targeted nanoparticle drug conjugates and uses thereof." This disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates. The methods outlined in these patents focus on making and using these conjugates to treat cancer effectively.

Career Highlights

Gardinier is currently associated with Elucida Oncology, Inc., where he continues to develop innovative solutions for cancer treatment. His work emphasizes the importance of targeted therapies in improving patient outcomes.

Collaborations

Some of his notable coworkers include Kai Ma and Aranapakam Mudumbai Venkatesan. Their collaborative efforts contribute to the advancement of research and development in the field of oncology.

Conclusion

Thomas Courtney Gardinier, II is a prominent figure in the realm of nanoparticle drug conjugates, with a focus on cancer treatment. His innovative patents and work at Elucida Oncology, Inc. highlight his commitment to improving therapeutic strategies for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…